Ann: US patent allowance for onCARlytics, page-4

ASX Announcement
US patent allowance for Imugene’s onCARlytics
• Core US patent allowed in major oncology market
• Patent provides method of composition and method of use protection to August 10,
2038
Sydney, Australia, 18 June 2025: Imugene Limited (ASX: IMU), a clinical-stage immuno
oncology company, is pleased to announce it has received a Notice of Allowance from the
US Patent and Trademark Office (USPTO) for patent application number 16/637,909
which protects its oncolytic virotherapy CF33-CD19 and its combination with CD19
targeting CAR T cell therapies.
The patent titled “ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES
THEREOF” (inventors Yuman Fong, Saul Priceman, Stephen Forman, Nanhai Chen and
Anthony Park from the City of Hope) protects the method of composition and method of
use of Imugene’s onCARlytics technology through to August 10 2038.
Exclusively licensed to Imugene, onCARlytics is a CD19-expressing oncolytic virus that
enters solid tumour cells and forces them to express the CD19 protein on the cell surface,
presenting a target for CD19 targeting therapies such as CAR T cellular therapies.
Imugene's ongoing OASIS dose escalation trial of onCARlytics is being conducted at up to
ten sites in the United States, with up to approximately 40 patients proposed to take part
in the trial.
Leslie Chong, Managing Director and CEO of Imugene, said:
“Imugene receiving this US patent allowance for the CF33-CD19 onCARlytics platform is a
crucial step forward for our IP position, with the US being the largest healthcare market in
the world. This follows patent allowance in China, an equally large cell therapy market,
earlier in 2025.”